Skip to Main Content
Contribute Try STAT+ Today

The Food and Drug Administration is threatening to fine Acceleron Pharma (XLRN) for failing to submit required information about a clinical trial to a federal registry, the first time the agency has taken such a step in response to ongoing calls for greater transparency into clinical studies.

In an April 27 letter sent to the drug maker, the FDA noted the results of a Phase 2 clinical trial that was run to test a pair of drugs for treating advanced kidney cancer had not been posted, even though the agency contacted the company last July about the issue. Acceleron now has until May 27 to post the data and an Acceleron spokesman wrote us that the company plans to do so.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.